期刊文献+

心肌梗死后心力衰竭患者血浆半乳糖凝集素3表达水平检测的意义 被引量:3

Expression of plasma Galectin-3 in patients with post-myocardial infarction heart failure
下载PDF
导出
摘要 目的探讨心肌梗死后心力衰竭患者血浆半乳糖凝集素3(Galectin-3)的表达水平及临床意义。方法 60例心力衰竭患者根据其既往病史,分为陈旧性心肌梗死组和非心肌梗死组,各30例,分别检测血浆Galectin-3表达水平,应用超声心动图评价心脏结构和心功能。结果陈旧性心肌梗死组血浆Galecint-3表达水平显著高于非心肌梗死组[(28.88±9.78)μg/L比(22.57±4.59)μg/L,P<0.05]。陈旧性心肌梗死组左心室射血分数显著低于非心肌梗死组[(51.38±9.75)%比(58.90±4.62)%,P<0.05]。血浆Galectin-3表达水平与左心房前后径呈正相关(r=0.612,P<0.01),与左心室射血分数呈负相关(r=-0.389,P<0.05)。结论心肌梗死后心力衰竭患者的血浆Galectin-3的表达水平较高。 Objective To explore the expression and its clinical significance of plasma Galectin-3 in postmyocardial infarction heart failure. Methods Plasma Galectin-3 and two-dimensional echocardiographic parameters were measured in 60 patients with heart failure. All the participants were divided into OMI group( n = 30,mean age80. 21 ± 4. 59ys) and non-MI group( n = 30,mean age 80. 74 ± 2. 99ys) according to the medical history. Results In the OMI group,the expression level of plasma Galectin-3 was higher than that of the non-MI group( 28. 88 ± 9. 78μg /L vs 22. 57 ± 4. 59μg / L),the LVEF was lower than the non-MI group( 51. 38 ± 9. 75% vs 58. 90 ± 4. 62%). Plasma concentration of Galectin-3 was negatively correlated with left ventricular systolic function( r =- 0. 389,P < 0. 05),positively correlated with left atrial diameter( r = 0. 612,P < 0. 01). Conclusion Compared to the non-MI group,the level of plasma Galectin-3 in OMI group is higher.
出处 《中国临床保健杂志》 CAS 2015年第1期5-7,共3页 Chinese Journal of Clinical Healthcare
关键词 心力衰竭 心肌梗死 心室重构 半乳糖凝集素3 Heart failure Myocardial infarction Ventricular remodeling Galectin 3
  • 相关文献

参考文献12

  • 1Peter Libby,Ira Tabas,Gabrielle Fredman,Edward A. Fisher.Inflammation and its Resolution as Determinants of Acute Coronary Syndromes[J]. Circulation Research . 2014 (12)
  • 2Alan H.B. Wu,Frank Wians,Allan Jaffe.Biological variation of galectin-3 and soluble ST2 for chronic heart failure: Implication on interpretation of test results[J]. American Heart Journal . 2013 (6)
  • 3Shweta R. Motiwala,Jackie Szymonifka,Arianna Belcher,Rory B. Weiner,Aaron L. Baggish,Patrick Sluss,Hanna K. Gaggin,Anju Bhardwaj,James L. Januzzi.Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study[J]. European Journal of Heart Failure . 2013 (10)
  • 4Dirk J. Lok,IJsbrand T. Klip,Sjoukje I. Lok,Pieta W. Bruggink-André de la Porte,Erik Badings,Jan van Wijngaarden,Adriaan A. Voors,Rudolf A. de Boer,Dirk J. van Veldhuisen,Peter van der Meer.Incremental Prognostic Power of Novel Biomarkers (Growth-Differentiation Factor-15, High-Sensitivity C-Reactive Protein, Galectin-3, and High-Sensitivity Troponin-T) in Patients With Advanced Chronic Heart Failure[J]. The American Journal of Cardiology . 2013
  • 5Laurent Calvier,Maria Miana,Pascal Reboul,Victoria Cachofeiro,Ernesto Martinez-Martinez,Rudolf A. de Boer,Fran?oise Poirier,Patrick Lacolley,Faiez Zannad,Patrick Rossignol,Natalia López-Andrés.Galectin-3 Mediates Aldosterone-Induced Vascular Fibrosis[J]. Arteriosclerosis, Thrombosis, and Vascular Biology . 2013 (1)
  • 6R. A. de Boer,D. J. van Veldhuisen,R. T. Gansevoort,A. C. Muller Kobold,W. H. van Gilst,H. L. Hillege,S. J. L. Bakker,P. van der Harst.The fibrosis marker galectin‐3 and outcome in the general population[J]. Journal of Internal Medicine . 2011 (1)
  • 7Dirk J. A. Lok,Peter Meer,Pieta W. Bruggink-André Porte,Erik Lipsic,Jan Wijngaarden,Hans L. Hillege,Dirk J. Veldhuisen.Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study[J]. Clinical Research in Cardiology . 2010 (5)
  • 8Nikolaos G. Frangogiannis.The immune system and cardiac repair[J]. Pharmacological Research . 2008 (2)
  • 9M. T. Elola,C. Wolfenstein-Todel,M. F. Troncoso,G. R. Vasta,G. A. Rabinovich.Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival[J]. Cellular and Molecular Life Sciences . 2007 (13)
  • 10Heechul Kim,Jeeyoung Lee,Jin Won Hyun,Jae Woo Park,Hong-gu Joo,Taekyun Shin.Expression and immunohistochemical localization of galectin-3 in various mouse tissues[J]. Cell Biology International . 2006 (7)

共引文献5

同被引文献41

  • 1Yamamoto K, Origasa H, Hori M. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail,2013,15:110- 118.
  • 2Little WC, Zile MR. HFpEF:eardiovascular abnormalities not just comorbidities. Circ Heart Fail, 2012,5 : 669-671.
  • 3Lok DJ, Lok SI, Bmggink-Andr6 de la Porte PW, et al. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Car- diol, 2013,102 : 103-110.
  • 4Lam CS, Donai E, Kraigher-Krainer E, et al. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail,2011,13: 18-28.
  • 5Liu ~, Haddad T, Dwivedi G. Heart failure with preserved ejec- tion fraction: current understanding and emerging concepts. Curt Opin Cardiol, 2013,28 : 187-196.
  • 6Poss J, Ewen S, Link A, et al. Acute and chronic heart failure- innovations of the new ESC guidelines and their underlying clini- cal trims. Dtsch Med Wochenschr,2013,138:1360-1364.
  • 7Ho JE, Liu C, Lyass A, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coil Cardiol, 2012,60 : 1249-1256.
  • 8Gruson D, Ko G. Galeetins testing: new promises for the diagnosis and risk stratification of chronic diseases? Clin Biochem, 2012,45 : 719-726.
  • 9Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev,2009,230: 160-171.
  • 10Song X, Qian X, Shen M, et al. Wagner Protein kinase C promotes cardiac fibrosis and heart failure by modulating ga[ectin-3 expression. Bioehim Biophys Acta,2015,1853:513- 521.

引证文献3

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部